Samsung Biologics Co Ltd
KRX:207940
Samsung Biologics Co Ltd
Cost of Revenue
Samsung Biologics Co Ltd
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Samsung Biologics Co Ltd
KRX:207940
|
Cost of Revenue
-₩1.9T
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Cost of Revenue
-₩2.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
K
|
Knotus Co Ltd
KOSDAQ:278650
|
Cost of Revenue
-₩16.4B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Cost of Revenue
-₩172.9B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Cost of Revenue
-₩12.4B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Cost of Revenue
-₩16.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
See Also
What is Samsung Biologics Co Ltd's Cost of Revenue?
Cost of Revenue
-1.9T
KRW
Based on the financial report for Dec 31, 2023, Samsung Biologics Co Ltd's Cost of Revenue amounts to -1.9T KRW.
What is Samsung Biologics Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-37%
Over the last year, the Cost of Revenue growth was -23%. The average annual Cost of Revenue growth rates for Samsung Biologics Co Ltd have been -36% over the past three years , -37% over the past five years .